Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Eptifibatide (Integrilin)].

L Holmvang1, P Grande

  • 1H:S Rigshospitalet, Hjertecentret, medicinsk afdeling B.

Ugeskrift for Laeger
|February 24, 2001
PubMed
Summary
This summary is machine-generated.

Eptifibatide (Integrilin) effectively inhibits platelet aggregation by blocking glycoprotein IIb/IIIa receptors. This medication reduces coronary events in specific acute coronary syndrome patients, supported by clinical trials and cost-benefit data.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Randomized trial of low-dose, ultrasound-assisted thrombolysis or heparin for pulmonary embolism.

Cardiovascular research·2026
Same author

[Home-based devices for the treatment of female urinary incontinence: A literature review].

Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie·2020
Same author

Drop-out from cardiovascular magnetic resonance in a randomized controlled trial of ST-elevation myocardial infarction does not cause selection bias on endpoints.

Clinical research in cardiology : official journal of the German Cardiac Society·2017
Same author

Accessory articulation of elongated anterior transverse process: a rare anatomical variant of the cervical spine depicted with CT and post-processing techniques.

Surgical and radiologic anatomy : SRA·2015
Same author

Prevalence of acute cardiac disorders in patients with suspected ST-segment elevation myocardial infarction and non-significant coronary artery disease.

Journal of electrocardiology·2014
Same author

Bladder cancer: innovative approaches beyond the diagnosis.

Current medicinal chemistry·2014
Same journal

[Mosaicism as a cause of Cowden syndrome].

Ugeskrift for laeger·2026
Same journal

[Thyrotoxic crisis with cardiogenic shock].

Ugeskrift for laeger·2026
Same journal

[Mindfulness-based cognitive therapy in the treatment of depression].

Ugeskrift for laeger·2026
Same journal

[Fitness].

Ugeskrift for laeger·2026
Same journal

[Risk of developing cataract related to fluoroscopy].

Ugeskrift for laeger·2026
Same journal

[Obturator hernia with small bowel ileus presenting as hip pain in an elderly woman].

Ugeskrift for laeger·2026
See all related articles

Area of Science:

  • Cardiology
  • Pharmacology
  • Biochemistry

Background:

  • Platelet aggregation is a key factor in acute coronary syndromes.
  • Glycoprotein IIb/IIIa receptors play a critical role in platelet activation.
  • Eptifibatide is a known inhibitor of this receptor pathway.

Purpose of the Study:

  • To summarize the established indications for eptifibatide (Integrilin) use.
  • To review recent clinical trial data supporting its efficacy.
  • To analyze the cost-benefit aspects of eptifibatide therapy.

Main Methods:

  • Review of recent clinical trials on eptifibatide.
  • Analysis of cost-benefit studies related to its application.
  • Synthesis of data on glycoprotein IIb/IIIa receptor blockade.

Related Experiment Videos

Main Results:

  • Eptifibatide demonstrates effectiveness in reducing coronary events.
  • Its use is indicated for patients with acute coronary syndromes without ST-segment elevation.
  • Clinical data and economic analyses support its therapeutic role.

Conclusions:

  • Eptifibatide is a valuable therapeutic agent for specific acute coronary syndrome patients.
  • Its mechanism involves specific glycoprotein IIb/IIIa receptor blockade.
  • Evidence from trials and cost-benefit analyses validates its clinical indications.